Odyssey Therapeutics announces executive changes
Odyssey Therapeutics, Inc. announced the appointment of Jeff Hermes as Executive Vice President of Enabling Sciences and promotion of Natalie Dales to the newly created position of Chief of Research Operations and Portfolio Strategy. In these roles, Dr. Hermes will oversee capability development and implementation for Odyssey’s platform approaches and technologies, and Dr. Dales will drive scientific strategy and facilitate collaboration across the organization.
Dr. Hermes is a seasoned professional with more than 30 years of experience in biochemistry, pharmacology, and in vitro sciences in the biopharmaceutical industry. Most recently, Dr. Hermes served as the Vice President of In Vitro Pharmacology at Kallyope
Dr. Dales brings over 20 years of experience leading small molecule drug discovery in pharmaceuticals and biotech. Dr. Dales most recently served as Odyssey’s Executive Vice President of Enabling Sciences. Previously, she spent over 15 years at Novartis, where she held roles of increasing responsibility, including Executive Director and Head of Portfolio and Strategy for Global Discovery Chemistry.
Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.